Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 9:47 PM
Ignite Modification Date:
2025-12-24 @ 9:47 PM
NCT ID:
NCT02551432
Brief Summary:
Patients with refractory SCLC. Patients will be treated with paclitaxel and pembrolizumab.
Detailed Description:
Open, uncontrolled, multi-center, phase II study.
Study:
NCT02551432
Study Brief:
Protocol Section:
NCT02551432